{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:52:25Z","timestamp":1777452745343,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF). The single-tablet regimen (STR) comprising elvitegravir, cobicistat, emtricitabine and TAF (E\/C\/F\/TAF) has demonstrated non-inferiority to the STR of E\/C\/F\/TDF in clinical studies, with high proportions of subjects achieving HIV-1 RNA &lt;50 copies\/ml at week 48 that were maintained through week 96. A resistance analysis of the combined Phase III clinical studies through 96 weeks is described here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genotypic and phenotypic susceptibility to antiretrovirals (ARVs) was evaluated for subjects with HIV-1 RNA \u2265400 copies\/ml at time of virological failure (VF) or early discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through week 96, VF resistance analyses were conducted for 24 subjects in each arm (2.8%, 24\/866 and 2.8%, 24\/867; for E\/C\/F\/TAF and E\/C\/F\/TDF arms, respectively). Primary resistance development to ARVs of the regimen occurred in 10 of 24 subjects in the E\/C\/F\/TAF arm, and 8 of 24 subjects in the E\/C\/F\/TDF arm (E\/C\/F\/TAF: M184V\/I, n=9; integrase strand-transfer inhibitor resistance-associated mutations [INSTI-RAMs], n=8; K65R\/N, n=2; E\/C\/F\/TDF: M184V\/I, n=6; INSTI-RAMs, n=5; K65R\/N, n=3). The emergent resistance mutations were similar between the treatment arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>E\/C\/F\/TAF achieved a high level of virological suppression in HIV-1 treatment-naive subjects through 96 weeks of treatment, with infrequent resistance development and comparable genotypic changes across both the E\/C\/F\/TAF and E\/C\/F\/TDF treatment groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3125","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T12:05:12Z","timestamp":1484136312000},"page":"443-446","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Infrequent Development of Drug Resistance in HIV-1-Infected Treatment-Naive Subjects after 96 Weeks of Treatment with Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide or Elvitegravir\/Cobicistat\/ Emtricitabine\/Tenofovir Disoproxil Fumarate"],"prefix":"10.1177","volume":"22","author":[{"given":"Nicolas","family":"Margot","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McCallister","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D","family":"Miller","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"bibr1-IMP3125","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.11.009"},{"key":"bibr2-IMP3125","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"bibr3-IMP3125","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182965d45"},{"key":"bibr4-IMP3125","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"key":"bibr5-IMP3125","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"bibr6-IMP3125","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.920-928.2000"},{"key":"bibr7-IMP3125","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"key":"bibr8-IMP3125","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1142731"},{"key":"bibr9-IMP3125","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:15Z","timestamp":1777380735000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.3851\/IMP3125"],"URL":"https:\/\/doi.org\/10.3851\/imp3125","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}